Welcome to our dedicated page for Radius Health news (Ticker: RDUS), a resource for investors and traders seeking the latest updates and insights on Radius Health stock.
Radius Recycling, Inc. generated company news around recycled metals processing, nonferrous and ferrous market conditions, finished steel operations, earnings releases, and operating initiatives in metal recovery and recycling services. Coverage also included governance changes and capital-structure matters tied to material agreements and shareholder actions.
In July 2025, Radius Recycling completed a merger and became a wholly owned subsidiary of Toyota Tsusho America, Inc. Subsequent RDUS-related developments center on the company's corporate-status transition, delisting and deregistration steps, and historical public-company disclosures.
Radius Health reported Q3 2021 net revenue of $57 million, a 13% increase from Q3 2020. However, total company revenue dropped by 27% year-over-year due to a lack of license revenue in the current quarter. Adjusted EBITDA was negative $11 million compared to a positive $9 million in the previous year. The company plans to lower its FY 2021 TYMLOS revenue forecast to $210-$220 million and adjusted EBITDA to a loss of $5-$15 million. Notably, the EMERALD study showed positive results for elacestrant, with regulatory submissions planned for 2022.
Summary not available.
Radius Health, Inc. (NASDAQ: RDUS) will release its third quarter financial results on November 8, 2021, followed by a conference call at 8:30 a.m. ET. Investors can join via a domestic dial-in at 1 (855) 404-2458 or internationally at 1 (430) 775-1272, using conference ID 9322858. A replay will be available the same day at 11:30 a.m. ET. Radius focuses on unmet medical needs in bone health and oncology, with its lead product, TYMLOS®, approved for high-risk postmenopausal women with osteoporosis.
Radius Health (NASDAQ: RDUS) and Menarini Group announced that their EMERALD study met its primary endpoints, demonstrating significant progression-free survival (PFS) in patients with ER+/HER2- advanced or metastatic breast cancer (mBC). Elacestrant, the first oral selective estrogen receptor degrader (SERD), showed positive results as a monotherapy compared to standard of care. Regulatory submissions are planned in the U.S. and EU for 2022, with data presentation scheduled at the San Antonio Breast Cancer Symposium in December 2021.
Radius Health announced positive topline results from the ATOM study, which evaluated abaloparatide for treating osteoporosis in men. The study met its primary endpoint, showing a significant increase in lumbar spine bone mineral density (BMD) at 12 months (8.5% vs. 1.2% placebo, p-value 0.0001). Secondary endpoints were also met, reflecting improvements in BMD at 6 months and at the hip and femoral neck after 12 months. The safety profile aligns with previous trials, and a supplemental new drug application (sNDA) is planned for Q1 2022.
Radius Health has updated the TYMLOS® label to clarify its mechanism of action, emphasizing its role in stimulating new bone formation. This change, effective September 20, 2021, aligns with the company's focus on treating postmenopausal women at high risk for fractures. Additionally, the company has welcomed Danielle Holtschlag as the new Head of Sales, bringing over 20 years of experience. Notably, Radius added approximately 3,000 new TYMLOS patients from July to August, reflecting a 13% increase year-over-year.
Radius Health (RDUS) reported Q2 2021 net revenue of $52 million, an increase of 3% year-over-year. The company achieved a significant reduction in adjusted EBITDA losses, reporting ($6) million compared to ($29) million in Q2 2020. However, FY 2021 TYMLOS revenue guidance was lowered from $250 million to $240 million. The company maintains a strong liquidity position with $100 million in cash. Adjusted net loss improved to ($10.5 million) from ($31.1 million) in the same quarter last year.
Radius Health (NASDAQ: RDUS) reported significant growth in new TYMLOS patients, with over 5,000 added in Q2 2021, marking a 40% increase year-over-year. The company expects topline results from the ATOM and wearABLe Phase 3 trials in the second half of 2021 and plans to resubmit regulatory filings in Europe by Q4 2021. Additionally, a pivotal trial for RAD011 targeting Prader-Willi Syndrome is set to begin either in Q4 2021 or Q1 2022. The company aims to demonstrate RAD011's efficacy and safety for FDA approval.
Summary not available.
Radius Health (NASDAQ: RDUS) recently revealed FDA Type C meeting minutes that clarify the Phase 2/3 study design for RAD011, a synthetic cannabidiol oral solution aimed at treating Prader-Willi Syndrome (PWS). The company plans to initiate the pivotal SCOUT study by the end of 2021 or early 2022, targeting approximately 200 patients across 30+ global sites, with top-line results expected in late 2024. RAD011 has received Orphan Drug and Fast Track designations, facilitating its regulatory pathway.